In a report released yesterday, Lorenzo Biasio from Credit Suisse maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $54.00. The company’s shares closed last Wednesday at $49.86.
According to TipRanks.com, Biasio is a 4-star analyst with an average return of 7.0% and a 61.3% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Coherus Biosciences, and Intuitive Surgical.
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $57.42, which is a 15.3% upside from current levels. In a report issued on July 29, Goldman Sachs also maintained a Hold rating on the stock with a $50.00 price target.
Pfizer’s market cap is currently $278.8B and has a P/E ratio of 11.40.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PFE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
- Credit Suisse Sticks to Their Buy Rating for Merck & Company (MRK)
- Credit Suisse Maintains a Buy Rating on Boston Scientific (BSX)
- Wells Fargo Keeps a Hold Rating on Lincoln National (LNC)
- Allstate (ALL) Gets a Sell Rating from Wells Fargo
- TMTG CEO Devin Nunes issues statement on the death of Congresswoman Jackie Walorski